Sun Pharmaceutical Industries has received regulatory approval from Brazil's health regulator ANVISA to manufacture and market semaglutide injections for treating adults with inadequately controlled Type 2 diabetes. According to Business Standard, the company plans to launch the product in the next few days through a partnership with Brazil-based Hypera Pharma. The product will be sold as a pre-filled, multi-dose injectable pen in two strengths — 2 mg/1.5 mL and 4 mg/3 mL — for once-weekly administration. This approval comes months after key semaglutide patent expiries opened the market to generic competition in several countries, with ANVISA clearing multiple semaglutide products following these patent expiries.
According to Sun Pharma, Brazil's semaglutide injectable market was valued at about $413 million for the 12 months ended June 2026, citing IQVIA data. As reported by CNBC TV18, semaglutide belongs to the fast-growing class of GLP-1 receptor agonists, which help regulate blood sugar levels and also aid weight loss. The molecule has emerged as one of the pharmaceutical industry's biggest growth drivers globally, spurred by demand for both diabetes and obesity treatments. The market is currently dominated by Novo Nordisk's blockbuster brands Ozempic and Wegovy, which have transformed the treatment landscape and sparked intense competition among global drugmakers. Systematix Institutional Equities estimates the addressable generic semaglutide opportunity across Canada and Brazil alone is near $500 million, making these markets key battlegrounds for players like Sun Pharma, Sandoz, and Dr. Reddy's. The Brazil approval adds to Sun Pharma's efforts to expand its footprint in the fast-growing GLP-1 segment globally, as demand for semaglutide-based therapies continues to rise for diabetes treatment.
ANVISA's prioritization of semaglutide medications began in August of last year, when the agency started accelerating evaluation of products based on semaglutide and liraglutide following a request from the Ministry of Health due to the need to expand national market supply. The agency implemented a plan of action with 125 initiatives, aimed at reducing medication registration backlogs and decreasing evaluation time. According to ANVISA, the mobilization has already shown results, with 11 of the 24 synthetic and biological medications covered by the call having their analysis concluded. As a consequence, six medications have already received approval, including the new registrations announced this Wednesday. The regulatory process involves clinical studies, technical analysis of documentation, and inspection of sterile production lines to verify product quality.
Sun Pharmaceutical Industries has received approval from Brazil's health regulator ANVISA to manufacture and market semaglutide injections in the South American country for adults with inadequately controlled Type 2 diabetes. According to reports from CNBC TV18, the drugmaker plans to launch the product in the coming days through a partnership with Hypera Pharma, one of Brazil's largest pharmaceutical companies. The product will be offered as a pre-filled, multi-dose injectable pen in two strengths, i.e 2 mg/1.5 mL and 4 mg/3 mL, allowing for once-weekly dosing. The Brazilian regulator approved Sun Pharma's generic semaglutide injection under the brand name Seemasun, marking the company's third major generic semaglutide market entry after India and South Africa. The company filed the regulatory intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on July 29, 2026, confirming that Sun Pharma holds the necessary manufacturing and marketing rights for the drug in the region.
Aalok Shanghvi, Chief Operating Officer at Sun Pharma, stated that the approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled Type 2 diabetes. According to Business Standard, he added that the approval reflects the strength of the company's development and manufacturing capabilities and its commitment to delivering high-quality medicines across global markets. Digvijay Singh, Regional Head, Brazil & LATAM, said the approval would strengthen the company's diabetes portfolio in the country and help expand patient access through its local partnership. The ANVISA approval represents a massive step forward for Sun Pharma's specialty and generic strategy in emerging markets, reinforcing its high-margin Rest of World formulations portfolio and helping offset US generics price pressure. This milestone, combined with the recent shareholder approval of the $11.75 billion Organon acquisition and upcoming Q1 FY27 results, provides strong near-term fundamental support for the company's expansion into high-value specialty therapies.
The Brazil approval comes as competition intensifies in Brazil's GLP-1 market, with ANVISA recently clearing multiple semaglutide products following patent expiries. According to Business Standard, Sandoz also received marketing authorisation for its semaglutide product, Owozy, developed in partnership with Adalvo. The approval positions Sun Pharma as a primary challenger in the global GLP-1 generic segment, with the company showcasing strong execution and regulatory compliance across international markets. Sun Pharma faces several key catalysts in the near term that could drive further growth, including the Q1 FY27 financial results announcement for July 31, 2026, which will provide insights into the Brazilian market performance, and regulatory approvals of the Organon acquisition in international jurisdictions. However, the company faces challenges including price erosion due to intense competition from other global and domestic generic manufacturers entering Brazil, potential intellectual property litigation from innovator Novo Nordisk, and currency volatility in the Latin American region affecting local revenue translation.
